Ultragenyx Pharmaceutical CAO Sells Over $37K in Stock

Theodore Alan Huizenga sold 1,632 shares of the company's stock, a 3.24% decrease in his ownership.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Chief Accounting Officer Theodore Alan Huizenga sold 1,632 shares of the company's stock on Monday, March 2nd. The shares were sold at an average price of $22.80, resulting in a total transaction of $37,209.60. Following the sale, Huizenga now owns 48,670 shares in the company, valued at $1,109,676.

Why it matters

Insider transactions, such as stock sales by company executives, can provide insights into a company's financial health and management's outlook. Huizenga's sale of over $37,000 worth of Ultragenyx stock may signal a change in his personal financial situation or a belief that the stock is overvalued.

The details

Huizenga's sale of 1,632 Ultragenyx shares represents a 3.24% decrease in his ownership of the company's stock. Ultragenyx is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. The company's commercial portfolio includes Crysvita, Mepsevii, and Dojolvi.

  • Huizenga sold the shares on Monday, March 2, 2026.

The players

Theodore Alan Huizenga

The Chief Accounting Officer of Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders.

Got photos? Submit your photos here. ›

The takeaway

Insider transactions, such as this stock sale by Ultragenyx's CAO, can provide insights into a company's financial health and management's outlook. However, without additional context, it's difficult to draw definitive conclusions about the company's future prospects.